PE · people undergoing bariatric surgery
1 finding from 1 review
Deep vein thrombosis · people undergoing bariatric surgery
Heparin showed no clear difference in DVT compared with pentasaccharide (low certainty).
1 finding from 1 review
Thrombocytopenia · people undergoing bariatric surgery
It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).
1 finding from 1 review
Total VTE · people undergoing bariatric surgery
Heparin showed no clear difference in VTE compared with pentasaccharide (low certainty).
1 finding from 1 review
Major bleeding · people undergoing bariatric surgery
It is very uncertain whether heparin changes major bleeding compared with pentasaccharide (very low certainty).
1 finding from 1 review
Early graft thrombosis · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Blood transfusion requirements · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Graft and patient survival · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐graft thrombosis · kidney transplant recipients
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
All cause mortality (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Adverse events (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Total VTE · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
Heparin showed no clear difference in PE (symptomatic, asymptomatic, non‐fatal) (timing not specified) compared with placebo (low certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found